H Brauch

Summary

Affiliation: Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology
Country: Germany

Publications

  1. pmc Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study
    Roger L Milne
    Genetic and Molecular Epidemiology Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre CNIO, Madrid, 28029, Spain
    Breast Cancer Res 12:R110. 2010
  2. ncbi request reprint Trichloroethylene exposure and specific somatic mutations in patients with renal cell carcinoma
    H Brauch
    Research Laboratory of the Women s Hospital Eppendorf, University of Hamburg, Germany
    J Natl Cancer Inst 91:854-61. 1999
  3. doi request reprint Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?
    Hiltrud Brauch
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology and University of Tuebingen, Auerbachstrasse 112, 70376 Stuttgart, Germany
    Eur J Cancer 45:2274-83. 2009
  4. ncbi request reprint Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen
    Werner Schroth
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
    JAMA 302:1429-36. 2009
  5. ncbi request reprint Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes
    Werner Schroth
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    J Clin Oncol 25:5187-93. 2007
  6. ncbi request reprint VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation
    H Brauch
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Cancer Res 60:1942-8. 2000
  7. ncbi request reprint DHPLC-based germline mutation screening in the analysis of the VHL tumor suppressor gene: usefulness and limitations
    B Klein
    , Stuttgart, Germany
    Hum Genet 108:376-84. 2001
  8. doi request reprint CYP2C19*17 is associated with decreased breast cancer risk
    Christina Justenhoven
    Molecular Mechanisms of Origin and Treatment of Breast Cancer, Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Breast Cancer Res Treat 115:391-6. 2009
  9. doi request reprint A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer
    Matjaz Rokavec
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology and Department of Gynecology, Robert Bosch Hospital, Stuttgart, Germany
    Cancer Res 68:9799-808. 2008
  10. ncbi request reprint One-carbon metabolism and breast cancer risk: no association of MTHFR, MTR, and TYMS polymorphisms in the GENICA study from Germany
    Christina Justenhoven
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, D 70376 Stuttgart, Germany
    Cancer Epidemiol Biomarkers Prev 14:3015-8. 2005

Detail Information

Publications37

  1. pmc Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study
    Roger L Milne
    Genetic and Molecular Epidemiology Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre CNIO, Madrid, 28029, Spain
    Breast Cancer Res 12:R110. 2010
    ....
  2. ncbi request reprint Trichloroethylene exposure and specific somatic mutations in patients with renal cell carcinoma
    H Brauch
    Research Laboratory of the Women s Hospital Eppendorf, University of Hamburg, Germany
    J Natl Cancer Inst 91:854-61. 1999
    ..We investigated whether TRI exposure produces RCC through a specific mutational effect on the VHL gene by analyzing VHL sequences in the RCCs of patients exposed to high, cumulative doses of TRI...
  3. doi request reprint Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?
    Hiltrud Brauch
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology and University of Tuebingen, Auerbachstrasse 112, 70376 Stuttgart, Germany
    Eur J Cancer 45:2274-83. 2009
    ....
  4. ncbi request reprint Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen
    Werner Schroth
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
    JAMA 302:1429-36. 2009
    ..The formation of active metabolites is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6) enzyme...
  5. ncbi request reprint Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes
    Werner Schroth
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    J Clin Oncol 25:5187-93. 2007
    ..We investigated the predictive value of genetic variants of CYP2D6, CYP2C19, and three other cytochrome P450 enzymes for tamoxifen treatment outcome...
  6. ncbi request reprint VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation
    H Brauch
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Cancer Res 60:1942-8. 2000
    ..009). This is the first evidence of frequent somatic VHL mutations at a particular site within exon 2 and an association of VHL mutations/hypermethylations with a standard prognostic factor...
  7. ncbi request reprint DHPLC-based germline mutation screening in the analysis of the VHL tumor suppressor gene: usefulness and limitations
    B Klein
    , Stuttgart, Germany
    Hum Genet 108:376-84. 2001
    ..Once a family-specific mutation has been established, DHPLC may be suitable for the rapid and cost-effective determination of VHL carrier status in family members...
  8. doi request reprint CYP2C19*17 is associated with decreased breast cancer risk
    Christina Justenhoven
    Molecular Mechanisms of Origin and Treatment of Breast Cancer, Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Breast Cancer Res Treat 115:391-6. 2009
    ..This protective effect seems to be stronger in combination with long-term intake of supplemental estrogens during hormone therapy...
  9. doi request reprint A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer
    Matjaz Rokavec
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology and Department of Gynecology, Robert Bosch Hospital, Stuttgart, Germany
    Cancer Res 68:9799-808. 2008
    ..35; 95% CI, 1.34-4.14). Our functional and patient-based results suggest that the TC21 -582C>T polymorphism improves prediction of tamoxifen treatment outcome in breast cancer...
  10. ncbi request reprint One-carbon metabolism and breast cancer risk: no association of MTHFR, MTR, and TYMS polymorphisms in the GENICA study from Germany
    Christina Justenhoven
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, D 70376 Stuttgart, Germany
    Cancer Epidemiol Biomarkers Prev 14:3015-8. 2005
  11. doi request reprint Pharmacogenomics of tamoxifen therapy
    Hiltrud Brauch
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Chem 55:1770-82. 2009
    ..Tamoxifen is a standard endocrine therapy for the prevention and treatment of steroid hormone receptor-positive breast cancer...
  12. ncbi request reprint Investigation of genetic variants of genes of the hemochromatosis pathway and their role in breast cancer
    Benny K Abraham
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    Cancer Epidemiol Biomarkers Prev 14:1102-7. 2005
    ..032). Our data suggest that variants of the hemochromatosis-transferrin receptor system have no direct effect on the incidence of breast cancer in Germany. Possible effects on tumor progression and prognosis remain elusive...
  13. ncbi request reprint ERCC2 genotypes and a corresponding haplotype are linked with breast cancer risk in a German population
    Christina Justenhoven
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, D 70376 Stuttgart, Germany
    Cancer Epidemiol Biomarkers Prev 13:2059-64. 2004
    ..49; 95% CI, 2.30-5.28). To our knowledge, this is the first study assigning breast cancer risk to both the ERCC2 genotype encoding Asp(312)Asp and the haplotype encoding Asp(312)/Gln(751)...
  14. ncbi request reprint A novel polymorphism in the promoter region of ERBB4 is associated with breast and colorectal cancer risk
    Matjaz Rokavec
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Cancer Res 13:7506-14. 2007
    ..To understand the role of genetic variations in the regulation of ERBB4 expression, we identified new polymorphisms and investigated their functional implication and risk association with breast and colorectal cancer...
  15. doi request reprint Polymorphic loci of E2F2, CCND1 and CCND3 are associated with HER2 status of breast tumors
    Christina Justenhoven
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Int J Cancer 124:2077-81. 2009
    ..We conclude that the analyzed polymorphisms located in E2F2, CCND1 and CCND3 are potential markers for HER2 status of breast tumors...
  16. ncbi request reprint Breast cancer: a candidate gene approach across the estrogen metabolic pathway
    Christina Justenhoven
    Molecular Mechanisms of Origin and Treatment of Breast Cancer, Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, Stuttgart, Germany
    Breast Cancer Res Treat 108:137-49. 2008
    ..The tested polymorphisms of the estrogen metabolic pathway may not play a direct role in breast cancer risk. Therefore, future association studies should be extended to other polymorphisms and other regulatory pathways...
  17. doi request reprint Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma
    T E Mürdter
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Pharmacol Ther 89:708-17. 2011
    ..For other enzymes tested, carriers of reduced-function CYP2C9 (*2, *3) alleles had lower plasma concentrations of active metabolites (P < 0.004), pointing to the role of additional pathways...
  18. ncbi request reprint The CYP1B1_1358_GG genotype is associated with estrogen receptor-negative breast cancer
    Christina Justenhoven
    Molecular Mechanisms of Origin and Treatment of Breast Cancer, Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, 70376, Stuttgart, Germany
    Breast Cancer Res Treat 111:171-7. 2008
    ..We conclude that the CYP1B1_1358_A>G polymorphism has an impact on ERalpha status in breast cancer in that the CYP1B1_1358_GG genotype known to encode higher CYP1B1 activity is associated with ERalpha negativity...
  19. ncbi request reprint A novel functional polymorphism in the transforming growth factor-beta2 gene promoter and tumor progression in breast cancer
    Julia Beisner
    Department of Clinical Chemistry, Robert Bosch Hospital, Auerbachstrasse 110, 70376 Stuttgart, Germany
    Cancer Res 66:7554-61. 2006
    ..18; 95% confidence interval, 1.44-18.62). We provide evidence that the TGFB2 -246ins polymorphism leads to enhanced TGF-beta(2) expression levels in vivo and might thereby contribute to tumor progression and development of metastases...
  20. doi request reprint The promoter C specific ERalpha isoform is associated with tamoxifen outcome in breast cancer
    Sandra Amaral
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart and University Tuebingen, Auerbachstrasse 112, 70376, Stuttgart, Germany
    Breast Cancer Res Treat 118:323-31. 2009
    ..41; CI 95% 1.45-8.04). The ESR1_C isoform had a prolonged mRNA half-life and a more relaxed 5'-UTR structure compared to ESR1_A isoform. ESR1_C levels may aid in the discrimination of patients' endocrine responsiveness...
  21. ncbi request reprint Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer
    Malgorzata Jaremko
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, University of Tubingen, Stuttgart, Germany
    Pharmacogenet Genomics 17:529-38. 2007
    ..Therefore, we tested the hypothesis of a relationship between event-free survival and genotype distributions of seven polymorphic DNA repair enzymes and four cell cycle regulators...
  22. doi request reprint [Pharmacogenomics: hype or hope?]
    M Schwab
    Dr Margarete Fischer Bosch Institut für Klinische Pharmakologie, Universitatsklinikum Tubingen, Auerbachstrasse 112, 70376 Stuttgart
    Dtsch Med Wochenschr 136:461-7. 2011
    ..The implementation of pharmacogenomics into clinical practise is a momentous future challenge that requires the establishment of interdisciplinary networks and professional organizations...
  23. doi request reprint No evidence for glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 in breast cancer risk
    Irena E Andonova
    Dr Margarte Fischer Bosch Institute of Clinical Pharmacology, 70376 Stuttgart, Germany
    Breast Cancer Res Treat 121:497-502. 2010
    ..We did not observe any breast cancer risk associations and conclude that it is unlikely that glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 participate in breast cancer susceptibility...
  24. ncbi request reprint MALDI-TOF MS and TaqMan assisted SNP genotyping of DNA isolated from formalin-fixed and paraffin-embedded tissues (FFPET)
    Malgorzata Jaremko
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Hum Mutat 25:232-8. 2005
    ..Our study shows for the first time that MALDI-TOF MS and TaqMan genotyping procedures provide reliable data, and are therefore applicable in studies that require large scale FFPET genotyping...
  25. pmc Estrogen-mediated downregulation of CD24 in breast cancer cells
    Benny Abraham Kaipparettu
    Division of Molecular Mechanisms of Origin and Treatment of Breast Cancer, Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Int J Cancer 123:66-72. 2008
    ..Together, our results show that CD24 is repressed by estrogen and that this repression is a direct transcriptional effect depending on ER alpha and histone deacetylases...
  26. doi request reprint Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis
    Bernd Frank
    Helmholtz University Group Molecular Epidemiology, Division of Molecular Genetic Epidemiology, German Cancer Research Center DKFZ, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany
    J Natl Cancer Inst 100:437-42. 2008
    ..10 (95% CI = 1.04 to 1.17, P = .001). Among the combined subset of 2795 familial breast cancer patients, the respective ORs were 1.27 (95% CI = 1.12 to 1.45, P = .0003) and 1.16 (95% CI = 1.06 to 1.27, P = .001)...
  27. ncbi request reprint Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors
    Michael Siegsmund
    Department of Urology, University Hospital Mannheim, University of Heidelberg, Theodor Kutzer Ufer 1 3, 68167 Heidelberg, Germany
    J Am Soc Nephrol 13:1847-54. 2002
    ..Especially T and TT carriers are at risk for developing non-CCRCC, i.e., papillary and chromophobe RCC as well as oncocytic adenomas...
  28. ncbi request reprint Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis
    Benny K Abraham
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, D 70376 Stuttgart, Germany
    Clin Cancer Res 11:1154-9. 2005
    ..Validation of these findings with respect to detection in clinical samples, prognosis, and clinical relevance is in demand...
  29. ncbi request reprint Factors modifying the association between hormone-replacement therapy and breast cancer risk
    Beate Pesch
    Berufsgenossenschaftliches Forschungsinstitut fur Arbeitsmedizin BGFA, Institut der Ruhr Universität Bochum, Burkle de la Camp Platz 1, 44789, Bochum, Gemany
    Eur J Epidemiol 20:699-711. 2005
    ..HRT users are different from non-users with respect to socio-economic and other characteristics. There may be women where the HRT-related risk could be modulated by other factors...
  30. ncbi request reprint German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer
    Muhammad U Rashid
    Division of Molecular Genome Analysis, German Cancer Research Center, B055, Im Neuenheimer Feld 580, 69120 Heidelberg, Germany
    Eur J Cancer 41:2896-903. 2005
    ..In patients with a high-risk profile however, CHEK2*1100delC was indicative for this risk and highest for early-onset breast cancer...
  31. ncbi request reprint Expression of xenobiotic and steroid hormone metabolizing enzymes in human breast carcinomas
    Susanne Haas
    Institute of Pathology, Medical Faculty of the University of Bonn, Sigmund Freud Street 25, D 53127 Bonn, Germany
    Int J Cancer 119:1785-91. 2006
    ..They particularly suggest that GST mu and pi expression may indicate a better prognosis and that strong CYP3A4/5 and CYP1B1 expression may be key features of nonfavourable prognosis...
  32. pmc Genome-wide association study identifies novel breast cancer susceptibility loci
    Douglas F Easton
    CR UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK
    Nature 447:1087-93. 2007
    ..05 level compared with an estimated 1,343 that would be expected by chance, indicating that many additional common susceptibility alleles may be identifiable by this approach...
  33. pmc Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms
    Yuan Ji
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 68:5997-6005. 2008
    ....
  34. ncbi request reprint A common coding variant in CASP8 is associated with breast cancer risk
    Angela Cox
    Sheffield University Medical School, Sheffield S10 2RX, UK
    Nat Genet 39:352-8. 2007
    ..02-1.13) and 1.16 (95% c.i.: 1.08-1.25), respectively; P(trend) = 2.8 x 10(-5)). These results demonstrate that common breast cancer susceptibility alleles with small effects on risk can be identified, given sufficiently powerful studies...
  35. pmc Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics
    Montserrat Garcia-Closas
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Marylan, United States of America
    PLoS Genet 4:e1000054. 2008
    ..Understanding the etiologic heterogeneity of breast cancer may ultimately result in improvements in prevention, early detection, and treatment...
  36. ncbi request reprint The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study
    Bernd Frank
    Helmholtz University Group Molecular Epidemiology, German Cancer Research Center, DKFZ, Im Neuenheimer Feld 581, 69120, Heidelberg, Germany
    Breast Cancer Res Treat 111:139-44. 2008
    ..The combined per allele odds ratio (OR) was 0.97 (95% confidence interval (CI), 95% CI = 0.93-1.02). The present result indicates that the CASP8 -652 6N del variant has no significant effect on BC risk in Europeans...